Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Intravenous administration of 50 mg lisdexamfetamine dimesylate to individuals with a history of drug abuse produced positive subjective responses on scales measuring "Drug Liking", "Euphoria", "Amphetamine Effects", and "Benzedrine Effects" that were greater than placebo but less than those produced by an equivalent dose (20 mg) of intravenous d-amphetamine
Participants randomized to retatrutide initiated treatment with 2 mg once-weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg)
Furthermore, the cardiovascular benefits of semaglutide demonstrated in the SUSTAIN-6 trial support its role as part of a broader cardiometabolic risk reduction strategy [23]
2018;155(4):1164-1176e2
11 , eaaq0702 (2018)
US$ 20.75
US$ 25.01
US$ 22.92
US$ 26.79
US$ 22.44
